For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

The problem with COPD is you have obstruction ... is to keep them from having exacerbations of their disease. What I usually tell patients to look for in a flare-up is: Is their mucus getting ...

COPD exacerbations apart from making you feel terrible for a few days, there is a risk that it could end up leading to a hospitalization. Which is obviously a concerning outcome where you may need ...

Considering all of the data and their limitations, questions still remain regarding the optimal treatment of COPD exacerbations ... only head-to-head trial to date. It is reasonable to recommend ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Administering the drug via injection during eosinophilic exacerbations reduced the need for further treatment ... type of flare-up involving elevated eosinophils (a white blood cell subtype) – ...

The major findings of this study of exacerbations of COPD can be ... few days after treatment initiation rather than at 5 or 10 days; however, this has not been studied to date and was not ...